Coherus Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $4.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Jason McCarthy has given his Buy rating due to a combination of factors that highlight Coherus Biosciences’ strategic positioning and potential for growth. The long-term follow-up data from the Phase 3 JUPITER-02 study, presented at ESMO Asia 2025, demonstrated that Loqtorzi, in combination with chemotherapy, significantly improves median overall survival in patients with recurrent or metastatic nasopharyngeal carcinoma compared to chemotherapy alone. This substantial reduction in the risk of death reinforces Loqtorzi’s position as the standard of care in this indication.
Additionally, the company’s strategic partnerships and collaborations, such as the license agreement between Dr. Reddy’s and Immutep, are expected to expand the reach of Loqtorzi across various tumor types. These collaborations, along with Loqtorzi’s unique position in the competitive PD-1 landscape, provide Coherus with a differentiated market opportunity valued at $150M-200M. The analyst’s valuation model also considers future revenue streams from other pipeline candidates, adjusted for commercial and clinical trial risks, supporting the overall positive outlook for Coherus Biosciences.
McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, SCYNEXIS, and Adial Pharmaceuticals. According to TipRanks, McCarthy has an average return of -8.6% and a 36.35% success rate on recommended stocks.